{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:44:14Z","timestamp":1765827854003},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death worldwide. Low-density lipoprotein cholesterol (LDL-C) is the primary cause of ASCVD and reducing LDL-C levels with statin therapy significantly reduces ASCVD risk; however, significant residual risk remains. Two monoclonal antibodies (mAbs), alirocumab and evolocumab, that target proprotein convertase subtilisin\/kexin-type 9 (PCSK9), reduce LDL-C levels by up to 60% when used in combination with statins and significantly reduce the risk of recurrent ASCVD events in both stable secondary prevention and acute coronary syndrome populations. Prespecified analyses of recent randomized controlled trials have shed light on how best to prioritize these therapies to maximize their value in select high-risk groups. These data have also informed recent clinical practice guidelines and scientific statements resulting in an expanded role for PCSK9-mAbs compared with previous guidelines, albeit there are notable differences between these recommendations. Ongoing research is exploring the long-term safety of PCSK9-mAbs and their role in the acute setting and patients without prior myocardial infarction or stroke. Novel therapies that inhibit PCSK9 synthesis via small interfering RNA, such as inclisiran, are also in development and may reduce LDL-C levels similar to PCSK9-mAbs, but with less frequent administration. Nonetheless, the PCSK9-mAbs are a breakthrough therapy and warrant consideration in very high-risk patients who are most likely to benefit. Such a personalized approach can help to ensure cost-effectiveness and maximize their value.<\/jats:p>","DOI":"10.1097\/fjc.0000000000000809","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T12:13:38Z","timestamp":1582114418000},"page":"410-420","source":"Crossref","is-referenced-by-count":13,"title":["PCSK9 Inhibitors in Secondary Prevention\u2014An Opportunity for Personalized Therapy"],"prefix":"10.1097","volume":"75","author":[{"given":"Chase","family":"Board","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapy & Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, VA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Chapman University School of Pharmacy, Irvine, CA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Section on Cardiovascular Medicine, Center for the Prevention of Cardiovascular Disease, Wake Forest Baptist Health, Winston-Salem, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dave L.","family":"Dixon","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy & Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, VA;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,5]]},"reference":[{"key":"R1-20230911","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2017.04.052","article-title":"Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015","volume":"70","author":"Roth","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"R2-20230911","first-page":"1","article-title":"Trends in cancer and heart disease death rates among adults aged 45\u201364: United States, 1999\u20132017","volume":"68","author":"Curtin","year":"2019","journal-title":"Natl Vital Stat Rep."},{"key":"R3-20230911","first-page":"1","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"0","author":"Ference","year":"2017","journal-title":"Eur Heart J."},{"key":"R4-20230911","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"R5-20230911","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jacl.2016.07.004","article-title":"A review of PCSK9 inhibition and its effects beyond LDL receptors","volume":"10","author":"Dixon","year":"2016","journal-title":"J Clin Lipidol."},{"key":"R6-20230911","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology."},{"key":"R7-20230911","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","article-title":"History of Discovery: the LDL receptor","volume":"29","author":"Goldstein","year":"2010","journal-title":"Arterioscler Thromb."},{"key":"R8-20230911","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1358\/dof.2013.38.7.1981967","article-title":"AMG-145. Anti-PCSK9 monoclonal antibody, treatment of lipoprotein disorders","volume":"38","author":"Stein","year":"2013","journal-title":"Drugs Fut."},{"key":"R9-20230911","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1194\/jlr.M051326","article-title":"Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin","volume":"55","author":"K\u00fchnast","year":"2014","journal-title":"J Lipid Res."},{"key":"R10-20230911","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med."},{"key":"R11-20230911","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med."},{"key":"R12-20230911","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med."},{"key":"R13-20230911","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40273-015-0355-y","article-title":"PCSK9 inhibitors: a technology worth paying for\u202f?","volume":"34","author":"Weintraub","year":"2016","journal-title":"Pharmacoeconomics."},{"key":"R14-20230911","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation."},{"key":"R15-20230911","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jacc.2019.03.013","article-title":"Alirocumab in patients with polyvascular disease and recent acute coronary syndrome","volume":"74","author":"Jukema","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"R16-20230911","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","article-title":"Clinical benefit of evolocumab by severity and extent of coronary artery disease analysis from Fourier","volume":"138","author":"Sabatine","year":"2018","journal-title":"Circulation."},{"key":"R17-20230911","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jacc.2019.07.015","article-title":"Effects of alirocumab on cardiovascular events after coronary bypass surgery","volume":"74","author":"Goodman","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"R18-20230911","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","article-title":"Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial","volume":"7","author":"Ray","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"R19-20230911","first-page":"1077","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"29","author":"Sattar","year":"2010","journal-title":"Rev Port Cardiol."},{"key":"R20-20230911","first-page":"1","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"8587","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"R21-20230911","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N Engl J Med."},{"key":"R22-20230911","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","article-title":"PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study","volume":"5","author":"Schmidt","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"R23-20230911","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ki.2010.536","article-title":"Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts","volume":"79","author":"Van Der Velde","year":"2011","journal-title":"Kidney Int."},{"key":"R24-20230911","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"R25-20230911","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"R26-20230911","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2018.12.022","article-title":"Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: the Atherosclerosis Risk in Communities study","volume":"282","author":"Saeed","year":"2019","journal-title":"Atherosclerosis."},{"key":"R27-20230911","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"R28-20230911","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40256-018-0303-2","article-title":"A meta-analysis of the effect of PCSK9-monoclonal antibodies on circulating lipoprotein (a) levels","volume":"19","author":"Cao","year":"2019","journal-title":"Am J Cardiovasc Drugs."},{"key":"R29-20230911","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation."},{"key":"R30-20230911","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1161\/CIRCULATIONAHA.117.028503","article-title":"Estimation of eligibility for proprotein convertase subtilisin\/kexin type 9 inhibitors and associated costs based on the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk): insights from the department of veterans affairs","volume":"135","author":"Virani","year":"2017","journal-title":"Circulation."},{"key":"R31-20230911","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jacl.2019.05.005","article-title":"Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit","volume":"13","author":"Robinson","year":"2019","journal-title":"J Clin Lipidol."},{"key":"R32-20230911","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J."},{"key":"R33-20230911","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.jacc.2019.08.1024","article-title":"Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia","volume":"74","author":"Koren","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"R34-20230911","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med."},{"key":"R35-20230911","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/FJC.0000000000000706","article-title":"Alirocumab in acute myocardial infarction: results from the Virginia commonwealth university alirocumab response trial (VCU-AlirocRT)","volume":"74","author":"Trankle","year":"2019","journal-title":"J Cardiovasc Pharmacol."},{"key":"R36-20230911","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS)","volume":"74","author":"Koskinas","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"R37-20230911","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1161\/CIRCRESAHA.117.310610","article-title":"A new approach to PCSK9 therapeutics","volume":"10032","author":"Wang","year":"2017","journal-title":"Circ Res."},{"key":"R38-20230911","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrcardio.2018.3","article-title":"Advances in lipid-lowering therapy through gene-silencing technologies","volume":"15","author":"Nordestgaard","year":"2018","journal-title":"Nat Rev Cardiol."},{"key":"R39-20230911","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med."}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FJC.0000000000000809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T02:08:44Z","timestamp":1694398124000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FJC.0000000000000809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/fjc.0000000000000809","relation":{},"ISSN":["0160-2446"],"issn-type":[{"value":"0160-2446","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}